GEA
TAK icon

Glen Eagle Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Glen Eagle Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$1.64K – 1071
2021
Q3 		$1.64K Hold
100
– – ﹤0.01% 948
2021
Q2 		$1.68K Buy
+100
New +$1.7K ﹤0.01% 935

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Glen Eagle Advisors's TAK Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2021, closing a stake of 100 shares — an estimated $1.64K sold.

Glen Eagle Advisors first reported a position in TAK in Q2 2021 and held it in 2 quarters. The position peaked at $1.68K in Q2 2021. 298 funds tracked by Wall St. Rank hold TAK as of Q4 2021.

  • Glen Eagle Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 100 Takeda Pharmaceutical shares in Q4 2021, an estimated $1.64K.
  • Glen Eagle Advisors first reported a position in Takeda Pharmaceutical in Q2 2021 and held it in 2 quarters.
  • Glen Eagle Advisors's Takeda Pharmaceutical position peaked at $1.68K in Q2 2021.
  • 298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.